CD4 and head and neck squamous cell carcinoma: Furthermore, a significantly decreased expression of the M1-marker MHCII suggests that HNSCC CM- treated MΦ may have a limited antigen presentation capacity, resulting in insufficient priming and proliferation of CD4+ T helper- cells.